Deutsche Bank AG acquired a new stake in Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 98,979 shares of the company's stock, valued at approximately $13,137,000. Deutsche Bank AG owned approximately 0.16% of Apogee Therapeutics as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its holdings in shares of Apogee Therapeutics by 0.5% during the fourth quarter. Wellington Management Group LLP now owns 4,746,585 shares of the company's stock worth $358,272,000 after buying an additional 22,884 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Apogee Therapeutics by 27.3% in the fourth quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company's stock worth $215,709,000 after buying an additional 612,193 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Apogee Therapeutics by 189,522.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company's stock worth $206,246,000 after buying an additional 2,731,015 shares in the last quarter. Janus Henderson Group PLC boosted its position in Apogee Therapeutics by 14.4% during the first quarter. Janus Henderson Group PLC now owns 2,360,596 shares of the company's stock worth $198,809,000 after acquiring an additional 297,992 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its position in Apogee Therapeutics by 72.4% during the fourth quarter. Perceptive Advisors LLC now owns 2,330,651 shares of the company's stock worth $175,918,000 after acquiring an additional 978,662 shares during the last quarter. Institutional investors and hedge funds own 79.04% of the company's stock.
Insider Transactions at Apogee Therapeutics
In other Apogee Therapeutics news, insider Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $132.60, for a total transaction of $3,500,640.00. Following the completion of the sale, the insider directly owned 179,248 shares in the company, valued at $23,768,284.80. This trade represents a 12.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 80,000 shares of the business's stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $132.54, for a total transaction of $10,603,200.00. Following the completion of the sale, the chief executive officer directly owned 1,015,987 shares in the company, valued at $134,658,916.98. This trade represents a 7.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 162,900 shares of company stock worth $20,344,950 in the last ninety days. 24.30% of the stock is currently owned by corporate insiders.
Apogee Therapeutics Price Performance
Shares of Apogee Therapeutics stock opened at $134.75 on Friday. Apogee Therapeutics Inc. has a 52 week low of $35.39 and a 52 week high of $134.88. The business's fifty day simple moving average is $129.31 and its 200-day simple moving average is $96.10. The firm has a market cap of $8.38 billion, a PE ratio of -31.05 and a beta of 0.34.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.07). As a group, equities analysts expect that Apogee Therapeutics Inc. will post -4.47 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the stock. BTIG Research cut shares of Apogee Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 12th. Craig Hallum set a $135.11 target price on Apogee Therapeutics and gave the stock a "hold" rating in a report on Monday, June 22nd. UBS Group lowered Apogee Therapeutics from a "buy" rating to a "neutral" rating and upped their price target for the company from $100.00 to $135.11 in a research report on Tuesday, June 23rd. Guggenheim cut Apogee Therapeutics from a "buy" rating to a "neutral" rating in a report on Tuesday, June 23rd. Finally, Mizuho reiterated a "neutral" rating and set a $135.00 price objective (up from $110.00) on shares of Apogee Therapeutics in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Apogee Therapeutics currently has an average rating of "Hold" and an average price target of $124.43.
Check Out Our Latest Analysis on APGE
Apogee Therapeutics Company Profile
(
Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
